Sex differences in HAART-associated dyslipidaemia

AIDS

Volumn 15, Issue 6, 2001, Pages 725-734

  Pernerstorfer Schoen, Heidemarie ^a   Jilma, Bernd ^b   Perschler, Alina ^a   Wichlas, Sibylle ^a   Schindler, Karin ^b   Schindl, Andreas ^b   Rieger, Armin ^a   Wagner, Oswald F ^b   Quehenberger, Peter ^b  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dyslipidaemia, soluble E selectin; HAART, protease inhibitors; Sex differences

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; E-SELECTIN; ENDOTHELIUM, VASCULAR; FEMALE; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; INSULIN; LEPTIN; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS; VIRAL LOAD;

EID: 0035853438     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200104130-00008     Document Type: Article

References (59)

1. Births and deaths: Preliminary data for 1998
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team
3. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection
4. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
5. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
6. Influence of protease inhibitor therapy on lipoprotein metabolism
7. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
8. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infeded patients
9. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study
10. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence
11. Women and AIDS in the United States: Epidemiology, natural history, and mediating mechanisms
12. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: Relationship to body composition, gonadal function, and protease inhibitor use
13. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study
14. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
15. Beneficial effects of protease inhibitors on body composition and energy expenditure: A comparison between HIV-infected and AIDS patients
16. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
17. Plasma lipids in HIV-infected patients: A prospective study in 95 patients
18. von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia
19. Hyperlipidemia under treatment with proteinase inhibitors
20. A simple, inexpensive method of determining total body water using a tracer dose of D20 and infrared absorption of biological fluids
21. Validation of the measurement of body composition from whole body bioelectric impedance
22. Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: Effects of race, sex, and disease
23. Persistent elevation and metabolic dependence of circulating Eselectin after delivery in women with gestational diabetes mellitus
24. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules
25. Procedural guidelines for performing immunophenotyping by flow cytometry
26. Asymptomatic atherosclerosis in HIV-positive patients: A case-control ultrasound study
27. Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients
28. Vascular complications associated with use of HIV protease inhibitors
29. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study
30. Leptin levels in HIV-positive patients treated with HAART
31. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
32. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters
33. Serum leptin concentrations in human immunodeficiency virus-infected men with low adiposity
34. Plasma leptin in chronic inflammatory bowel disease and HIV: Implications for the pathogenesis of anorexia and weight loss
35. Serum leptin levels in the acquired immunodeficiency syndrome
36. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
37. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men
38. Leptin concentrations and insulin sensitivity in normoglycemic men
39. Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: Effects of dietary fat content and sustained weight loss
40. Determinants of increased energy expenditure in HIV-infected women
41. Sex steroids, insulin, and arterial stiffness in women and men
42. Primary and subsequent coronary risk appraisal: New results from the Framingham study
43. Leptin promotes aggregation of human platelets via the long form of its receptor
44. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women
45. Leptin regulates proinflammatory immune responses
46. Leptin induces oxidative stress in human endothelial cells
47. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk
48. Soluble adhesion molecules and endothelial cell damage in HIV infected patients
49. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients
50. Effect of the antioxidants selenium and beta-carotene on HIV-related endothelium dysfunction
51. Infections and systemic vasculitis
52. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study
53. Relationship between endothelial cell markers and arterial stenosis in peripheral and carotid artery disease
54. Effects of 17 betaestradiol on circulating adhesion molecules
55. The influence of age, gender and ABO blood group on soluble endothelial cell markers and adhesion molecules
56. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
57. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to neviraplne
58. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
59. The mechanism of insulin resistance caused by HIV protease inhibitor therapy